TCIM
ABEO icon

TIAA CREF Investment Management’s Abeona Therapeutics ABEO Stock Holding History

TIAA CREF Investment Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$433K Sell
2,354
-22
-0.9% -$3.93K ﹤0.01% 2654
2018
Q4 		$424K Sell
2,376
-29
-1% -$6.33K ﹤0.01% 2641
2018
Q3 		$770K Sell
2,405
-215
-8% -$76.3K ﹤0.01% 2542
2018
Q2 		$1.05M Sell
2,620
-53
-2% -$23.2K ﹤0.01% 2473
2018
Q1 		$959K Buy
2,673
+22
+0.8% +$8.17K ﹤0.01% 2463
2017
Q4 		$1.05M Sell
2,651
-62
-2% -$25.6K ﹤0.01% 2440
2017
Q3 		$1.16M Buy
2,713
+24
+0.9% +$6.45K ﹤0.01% 2450
2017
Q2 		$430K Buy
+2,689
New +$367K ﹤0.01% 2924
2016
Q2 		– Sell
-1,631
Closed -$104K – 3151
2016
Q1 		$104K Hold
1,631
– – ﹤0.01% 3031
2015
Q4 		$137K Buy
1,631
+283
+21% +$28.4K ﹤0.01% 3090
2015
Q3 		$137K Hold
1,348
– – ﹤0.01% 3062
2015
Q2 		$171K Buy
+1,348
New +$202K ﹤0.01% 3126

Other funds holding ABEO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

TIAA CREF Investment Management's ABEO Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Abeona Therapeutics (ABEO) stake by 0.93% in Q1 2019, selling an estimated $3.93K and leaving 2,354 shares worth $433K. The position accounts for ﹤0.01% of the portfolio, ranked #2654.

TIAA CREF Investment Management first reported a position in ABEO in Q2 2015 and has held it in 12 quarters since. The position peaked at $1.16M in Q3 2017. 87 funds tracked by Wall St. Rank hold ABEO as of Q1 2019.

  • TIAA CREF Investment Management held 2,354 shares of Abeona Therapeutics worth $433K as of Q1 2019.
  • TIAA CREF Investment Management sold 22 Abeona Therapeutics shares in Q1 2019, an estimated $3.93K.
  • Abeona Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2654 holding.
  • TIAA CREF Investment Management first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 12 quarters since.
  • TIAA CREF Investment Management's Abeona Therapeutics position peaked at $1.16M in Q3 2017.
  • 87 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.